• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kalvista Pharmaceuticals Inc (NQ: KALV )

    15.39 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 15.39
    Bid (Size) 6.200 (1)
    Ask (Size) 24.62 (2)
    Prev. Close 15.39
    Today's Range 15.39 - 15.39
    52wk Range 7.210 - 16.88
    Shares Outstanding 34,233,643
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024
    KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +26.67%
    +26.67%
    1 Month
    +31.31%
    +31.31%
    3 Month
    +37.29%
    +37.29%
    6 Month
    +23.02%
    +23.02%
    1 Year
    +61.83%
    +61.83%

    More News

    Read More
    KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    Recap: KalVista Pharma Q3 Earnings
    Via Benzinga
    KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From KalVista Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.